Guerrero-Hue and colleagues [55] also focused on NRF2 as a therapeutic option and discussed the known clinical trials of NRF2 inducers in CKD of different etiologies (e.g., CKD, ADPKD and Alport, CKD with T1DM/T2DM/IgA nephropathy). Here, NFE2L2 is linked to type 1 diabetes mellitus.